93 results on '"de Boer, Rudolf A."'
Search Results
2. ECG-only explainable deep learning algorithm predicts the risk for malignant ventricular arrhythmia in phospholamban cardiomyopathy.
- Author
-
van de Leur, Rutger R., de Brouwer, Remco, Bleijendaal, Hidde, Verstraelen, Tom E., Mahmoud, Belend, Perez-Matos, Ana, Dickhoff, Cathelijne, Schoonderwoerd, Bas A., Germans, Tjeerd, Houweling, Arjan, van der Zwaag, Paul A., Cox, Moniek G.P.J., Peter van Tintelen, J., te Riele, Anneline S.J.M., van den Berg, Maarten P., Wilde, Arthur A.M., Doevendans, Pieter A., de Boer, Rudolf A., and van Es, René
- Abstract
Phospholamban (PLN) p.(Arg14del) variant carriers are at risk for development of malignant ventricular arrhythmia (MVA). Accurate risk stratification allows timely implantation of intracardiac defibrillators and is currently performed with a multimodality prediction model. This study aimed to investigate whether an explainable deep learning–based approach allows risk prediction with only electrocardiogram (ECG) data. A total of 679 PLN p.(Arg14del) carriers without MVA at baseline were identified. A deep learning–based variational auto-encoder, trained on 1.1 million ECGs, was used to convert the 12-lead baseline ECG into its FactorECG, a compressed version of the ECG that summarizes it into 32 explainable factors. Prediction models were developed by Cox regression. The deep learning–based ECG-only approach was able to predict MVA with a C statistic of 0.79 (95% CI, 0.76–0.83), comparable to the current prediction model (C statistic, 0.83 [95% CI, 0.79–0.88]; P =.054) and outperforming a model based on conventional ECG parameters (low-voltage ECG and negative T waves; C statistic, 0.65 [95% CI, 0.58–0.73]; P <.001). Clinical simulations showed that a 2-step approach, with ECG-only screening followed by a full workup, resulted in 60% less additional diagnostics while outperforming the multimodal prediction model in all patients. A visualization tool was created to provide interactive visualizations (https://pln.ecgx.ai). Our deep learning–based algorithm based on ECG data only accurately predicts the occurrence of MVA in PLN p.(Arg14del) carriers, enabling more efficient stratification of patients who need additional diagnostic testing and follow-up. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER.
- Author
-
BUTT, JAWAD H., JERING, KAROLA, DE BOER, RUDOLF A., CLAGGETT, BRIAN L., DESAI, AKSHAY S., HERNANDEZ, ADRIAN F., INZUCCHI, SILVIO E., JHUND, PARDEEP S., KØBER, LARS, KOSIBOROD, MIKHAIL N., LAM, CAROLYN S.P., MARTINEZ, FELIPE A., PONIKOWSKI, PIOTR, SABATINE, MARC S., SHAH, SANJIV J., VADUGANATHAN, MUTHIAH, LANGKILDE, ANNA MARIA, BENGTSSON, OLOF, PETERSSON, MAGNUS, and SJÖSTRAND, MIKAELA
- Abstract
• Whether dapagliflozin is beneficial in patients with sleep apnea and heart failure, across the range of ejection fractions, is unknown. • In a pooled individual-level meta-analysis of DAPA-HF and DELIVER, investigator-reported sleep apnea was associated with a greater risk of worsening heart failure events. • Dapagliflozin, compared with placebo, reduced the risk of clinical outcomes and improved health-related quality of life in patients with and without sleep apnea. Sleep apnea is more common in patients with heart failure (HF) than in the general population, but little is known about its association with clinical outcomes in various HF phenotypes or how it might modify the effect of HF therapy. To examine the prevalence of sleep apnea, its association with outcomes and the effects of dapagliflozin in patients with HF with and without sleep apnea in a pooled analysis of 2 trials comparing dapagliflozin to placebo in HFrEF (DAPA-HF trial) and HFmrEF/HFpEF (DELIVER trial). A history of sleep apnea was investigator-reported. The primary outcome was a composite of worsening HF or cardiovascular death. The prevalence of sleep apnea was 5.7% and 7.8% in patients with HFrEF and HFmrEF/HFpEF, respectively. The primary outcome occurred at a rate of 16.0 in participants with sleep apnea compared to 10.6 per 100 person-years in those without (adjusted HR 1.29 [95%CI, 1.10–1.52]). Compared with placebo, dapagliflozin reduced the risk of the primary endpoint to the same extent in patients with (HR 0.78 [95% CI, 0.59–1.03]) and without sleep apnea (HR 0.79 [0.72–0.87]) [P interaction = 0.93]. The beneficial effects of dapagliflozin on other clinical outcomes and symptom burden, physical function, and quality of life were consistent in participants with and without sleep apnea. In DAPA-HF and DELIVER, the true prevalence of sleep apnea was likely underestimated. An investigator-reported history of sleep apnea was associated with higher rates of worsening HF events. The benefits of dapagliflozin on clinical outcomes were consistent in patients with and without sleep apnea. Unique identifiers: NCT01920711 In a pooled analysis of the DAPA-HF and DELIVER trials of more than 11,000 patients with heart failure (HF) across the range of ejection fractions, an investigator-reported history of sleep apnea was associated with higher rates of worsening HF events but not mortality. The beneficial effects of dapagliflozin on clinical outcomes were consistent in patients with and without sleep apnea. These findings provide further evidence for dapagliflozin as a new treatment option for patients with heart failure across the range of ejection fractions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population
- Author
-
Suthahar, Navin, Meijers, Wouter C., Brouwers, Frank P., Heerspink, Hiddo J.L., Gansevoort, Ron T., van der Harst, Pim, Bakker, Stephan J.L., and de Boer, Rudolf A.
- Published
- 2018
- Full Text
- View/download PDF
5. The LifeLines Cohort Study: Prevalence and treatment of cardiovascular disease and risk factors
- Author
-
van der Ende, M. Yldau, Hartman, Minke H.T., Hagemeijer, Yanick, Meems, Laura M.G., de Vries, Hendrik Sierd, Stolk, Ronald P., de Boer, Rudolf A., Sijtsma, Anna, van der Meer, Peter, Rienstra, Michiel, and van der Harst, Pim
- Published
- 2017
- Full Text
- View/download PDF
6. Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER.
- Author
-
Bhatt, Ankeet S., Lindholm, Daniel, Nilsson, Ann, Zaozerska, Natalia, Claggett, Brian L., Vaduganathan, Muthiah, Kosiborod, Mikhail N., Lam, Carolyn S.P., Hernandez, Adrian F., Martinez, Felipe A., Inzucchi, Silvio E, Shah, Sanjiv J., de Boer, Rudolf A., Desai, Akshay, Jhund, Pardeep S., Langkilde, Anna Maria, Petersson, Magnus, McMurray, John J.V., and Solomon, Scott D.
- Abstract
Catastrophic disruptions in care delivery threaten the operational efficiency and potentially the validity of clinical research efforts, in particular randomized clinical trials. Most recently, the COVID-19 pandemic affected essentially all aspects of care delivery and clinical research conduct. While consensus statements and clinical guidance documents have detailed potential mitigation measures, few real-world experiences detailing clinical trial adaptations to the COVID-19 pandemic exist, particularly among, large, global registrational cardiovascular trials. We outline the operational impact of COVID-19 and resultant mitigation measures in the Dapagliflozin Evaluation to Improve the LIVEs of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial, one of the largest and most globally diverse experiences with COVID-19 of any cardiovascular clinical trial to date. Specifically, we address the needed coordination between academic investigators, trial leadership, clinical sites, and the supporting sponsor to ensure the safety of participants and trial staff, to maintain the fidelity of trial operations, and to prospectively adapt statistical analyses plans to evaluate the impact of COVID-19 and the pandemic at large on trial participants. These discussions included key operational issues such as ensuring delivery of study medications, adaptations to study visits, enhanced COVID-19 related endpoint adjudication, and protocol and analytical plan revisions. Our findings may have important implications for establishing consensus on prospective contingency planning in future clinical trials. Clinicaltrial.gov: NCT03619213. NCT03619213. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND
- Author
-
van der Velde, A. Rogier, Meijers, Wouter C., van den Heuvel, Edwin R., Bakker, Stephan J., van Gilst, Wiek H., van der Harst, Pim, Hillege, Hans, and de Boer, Rudolf A.
- Published
- 2016
- Full Text
- View/download PDF
8. Value of genetic testing in the diagnosis and risk stratification of arrhythmogenic right ventricular cardiomyopathy.
- Author
-
de Brouwer, Remco, Bosman, Laurens P., Gripenstedt, Sophia, Wilde, Arthur A.M., van den Berg, Maarten P., Peter van Tintelen, J., de Boer, Rudolf A., te Riele, Anneline S.J.M., and Netherlands ACM Registry
- Abstract
Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is characterized by risk of malignant ventricular arrhythmia (VA). ARVC is diagnosed using an array of clinical tests in the consensus-based Task Force Criteria (TFC), one of which is genetic testing.Objective: The purpose of this study was to investigate the value of genetic testing in diagnosing ARVC and its relation to the occurrence of first malignant VA.Methods: A multicenter cohort of patients with ARVC was scored using the revised 2010 TFC with and without genetic criterion, analyzing any resulting loss or delay of diagnosis. Malignant VA was defined as sustained VA (≥30-second duration at ≥100 beats/min or requiring intervention).Results: We included 402 subjects (221 [55%] male; 216 [54%] proband; 40 [27-51] years old at presentation) who were diagnosed with definite ARVC. A total of 232 subjects (58%) fulfilled genetic testing criteria. Removing the genetic criterion caused loss of diagnosis in 18 patients (4%) (11 of 216 probands [5%] and 7 of 186 relatives [4%]) and delay of diagnosis by ≥30 days in 22 patients (5%) (21 of 216 probands [10%] and 1 of 186 relative [0.5%]). A first malignant VA occurred in no patients who lost diagnosis and in 3 patients (3 of 216 probands [1%] and no relatives) during their diagnosis delay, none fatal. Time-to-event analysis showed no significant difference in time from diagnosis to malignant VA between pathogenic variant carriers and noncarriers.Conclusion: Disregarding the genetic criterion of the TFC caused loss or delay of diagnosis in 10% of patients with ARVC (40 of 402). Malignant VA occurred in 1% of cases with lost or delayed diagnosis (3 of 402), none fatal. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Urinary potassium excretion and mortality risk in community-dwelling individuals with and without obesity.
- Author
-
Yeung, Stanley M H, Nooteboom, Anne, Hoorn, Ewout J, Rotmans, Joris I, Vogt, Liffert, de Boer, Rudolf A, Gansevoort, Ron T, Navis, Gerjan, Bakker, Stephan J L, and De Borst, Martin H
- Subjects
MORTALITY risk factors ,OBESITY ,HYPERTENSION ,CONFIDENCE intervals ,POTASSIUM ,RISK assessment ,INDEPENDENT living ,DESCRIPTIVE statistics ,WAIST circumference ,BODY mass index ,LONGITUDINAL method ,PROPORTIONAL hazards models - Abstract
Background Potassium intake has been shown to be inversely associated with blood pressure and premature mortality. Previous studies have suggested that the association between potassium intake and blood pressure is modified by obesity, but whether obesity similarly influences the association between potassium intake and mortality is unclear. Objectives We investigated whether potassium intake, reflected by 24-h urinary excretion, is associated with all-cause mortality, and explored potential effect modification by obesity. Methods We performed a prospective cohort study in community-dwelling individuals. The association between urinary potassium excretion and all-cause mortality was investigated by using multivariable Cox regression. We performed multiplicative interaction analysis and subgroup analyses according to BMI and waist circumference. Results In 8533 individuals (50% male), the mean age was 50 ± 13 y, mean urinary potassium excretion was 71 ± 21 mmol/24 h, median BMI (in kg/m
2 ) was 25.6 (IQR: 23.1, 28.4) and mean waist circumference was 89 ± 13 cm. During median follow-up of 18.4 (IQR: 13.5, 18.8) y, 1663 participants died. Low urinary potassium excretion (first compared with third sex-specific quintile) was associated with an increased mortality risk (fully adjusted HR: 1.38; 95% CI: 1.18, 1.61), P < 0.001, irrespective of body dimensions (HR range for all body dimensions: 1.36–1.70, all P < 0.05). High urinary potassium excretion (fifth compared with third quintile) was associated with increased mortality risk in participants with obesity (BMI ≥30; HR: 1.52; CI: 1.00, 2.30), but not in participants without obesity (BMI: <25; HR: 0.89; 95% CI: 0.62, 1.26; P -interaction = 0.001). Conclusions Low potassium intake was associated with increased mortality risk in community-dwelling individuals. In individuals with obesity, high potassium intake was also associated with increased mortality risk. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
10. Erythropoietin in cardiac disease: New features of an old drug
- Author
-
Ruifrok, Willem-Peter T., de Boer, Rudolf A., Westenbrink, B. Daan, van Veldhuisen, Dirk J., and van Gilst, Wiek H.
- Published
- 2008
- Full Text
- View/download PDF
11. Lifestyle components: Self-reported physical activity, nutritional status, sleep quality and incident atrial fibrillation
- Author
-
Siland, Joylene E., Zwartkruis, Victor, Geelhoed, Bastiaan, de Boer, Rudolf A., van Gelder, Isabelle C., van der Harst, Pim, and Rienstra, Michiel
- Published
- 2020
- Full Text
- View/download PDF
12. Sex-specific aspects of phospholamban cardiomyopathy: The importance and prognostic value of low-voltage electrocardiograms.
- Author
-
de Brouwer, Remco, Meems, Laura M.G., Verstraelen, Tom E., Mahmoud, Belend, Proost, Virginnio, Wilde, Arthur A.M., Bosman, Laurens P., van Drie, Esmée, van der Zwaag, Paul A., van Tintelen, J. Peter, Houweling, Arjan C., van den Berg, Maarten P., and de Boer, Rudolf A.
- Abstract
Background: A pathogenic variant in the gene encoding phospholamban (PLN), a protein that regulates calcium homeostasis of cardiomyocytes, causes PLN cardiomyopathy. It is characterized by a high arrhythmic burden and can progress to severe cardiomyopathy. Risk assessment guides implantable cardioverter-defibrillator therapy and benefits from personalization. Whether sex-specific differences in PLN cardiomyopathy exist is unknown.Objective: The purpose of this study was to improve the accuracy of PLN cardiomyopathy diagnosis and risk assessment by investigating sex-specific aspects.Methods: We analyzed a multicenter cohort of 933 patients (412 male, 521 female) with the PLN p.(Arg14del) pathogenic variant following up on a recently developed PLN risk model. Sex-specific differences in the incidence of risk model components were investigated: low-voltage electrocardiogram (ECG), premature ventricular contractions, negative T waves, and left ventricular ejection fraction.Results: Sustained ventricular arrhythmias (VAs) occurred in 77 males (18.7%) and 61 females (11.7%) (P = .004). Of the 933 cohort members, 287 (31%) had ≥1 low-voltage ECG during follow-up (180 females [63%], 107 males [37%]; P = .006). Female sex, age, age at clinical presentation, and proband status predicted low-voltage ECG during follow-up (area under the curve: 0.78). Sustained VA-free survival was lowest in males with low-voltage ECG (P <.001).Conclusion: Low-voltage ECGs predict sustained VA and are a component of the PLN risk model. Low-voltage ECGs are more common in females, yet prognostic value is greater in males. Future studies should determine the impact of this difference on the risk prediction of PLN cardiomyopathy and possibly other cardiomyopathies. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
13. Early Mechanical Alterations in Phospholamban Mutation Carriers: Identifying Subclinical Disease Before Onset of Symptoms.
- Author
-
Taha, Karim, te Rijdt, Wouter P., Verstraelen, Tom E., Cramer, Maarten J., de Boer, Rudolf A., de Bruin-Bon, Rianne H.A.C.M., Bouma, Berto J., Asselbergs, Folkert W., Wilde, Arthur A.M., van den Berg, Maarten P., and Teske, Arco J.
- Abstract
This study aimed to explore echocardiographic characteristics of phospholamban (PLN) p.Arg14del mutation carriers to investigate whether structural and/or functional abnormalities could be identified before onset of symptoms. Carriers of the genetic PLN p.Arg14del mutation may develop arrhythmogenic and/or dilated cardiomyopathy. Overt disease is preceded by a pre-symptomatic phase of variable length in which disease expression seems to be absent. PLN p.Arg14del mutation carriers with an available echocardiogram were included. Mutation carriers were classified as pre-symptomatic if they had no history of ventricular arrhythmias (VAs), a premature ventricular complex count of <500/24 h, and a left ventricular (LV) ejection fraction of ≥45%. In addition, we included 70 control subjects with similar age and sex distribution as the pre-symptomatic mutation carriers. Comprehensive echocardiographic analysis (including deformation imaging) was performed. The final study population consisted of 281 PLN p.Arg14del mutation carriers, 139 of whom were classified as pre-symptomatic. In comparison to control subjects, pre-symptomatic mutation carriers had lower global longitudinal strain and higher LV mechanical dispersion (both p < 0.001). In addition, post-systolic shortening (PSS) in the LV apex was observed in 43 pre-symptomatic mutation carriers (31%) and in none of the control subjects. During a median follow-up of 3.2 years (interquartile range: 2.1 to 5.6 years) in 104 pre-symptomatic mutation carriers, nonsustained VA occurred in 13 (13%). Presence of apical PSS was the strongest echocardiographic predictor of VA (multivariable hazards ratio: 5.11; 95% confidence interval [CI]: 1.37 to 19.08; p = 0.015), which resulted in a negative predictive value of 96% (95% CI: 89% to 98%) and a positive predictive value of 29% (95% CI: 21% to 40%). Global and regional LV mechanical alterations in PLN p.Arg14del mutation carriers precede arrhythmic symptoms and overt structural disease. Pre-symptomatic mutation carriers with normal deformation patterns in the apex are at low risk of developing VA within 3 years, whereas mutation carriers with apical PSS appear to be at higher risk. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Preoperative cardiac screening using NT-proBNP in obese patients 50 years and older undergoing bariatric surgery: a study of 310 consecutive patients.
- Author
-
van Veldhuisen, Sophie L., van Woerden, Gijs, Hemels, Martin E.W., America, Yves G.C. J., de Boer, Rudolf A., Rienstra, Michiel, van Veldhuisen, Dirk J., and Hazebroek, Eric J.
- Abstract
Obesity is associated with cardiovascular (CV) risk factors and diseases. Because bariatric surgery is increasingly performed in relatively elderly patients, a risk for pre- and postoperative CV complications exists. We aimed to assess the value of plasma N-terminal-probrain natriuretic peptide (NT-proBNP) as a CV screening tool. High-volume bariatric center. Between June 2019 and January 2020, all consecutive bariatric patients 50 years and older underwent preoperative NT-proBNP assessment in this cohort study to screen for CV disease. Patients with elevated NT-proBNP (≥125 pg/mL) were referred for further cardiac evaluation, including electrocardiography and echocardiography. We included 310 consecutive patients (median age, 56 years; 79% female; body mass index = 43±6.5 kg/m
2 ). A history of CV disease was present in 21% of patients, mainly atrial fibrillation (7%) and coronary artery disease (10%). A total of 72 patients (23%) had elevated NT-proBNP levels, and 67 of them underwent further cardiac workup. Of these 67 patients, electrocardiography (ECG) showed atrial fibrillation in 7 patients (10%). On echocardiography, 3 patients had left ventricular ejection fraction (LVEF) <40%, 9 patients had LVEF 40%–49%, and 13 patients had LVEF ≥50% with structural and/or functional remodeling. In 2 patients, elevated NT-proBNP prompted workup leading to a diagnosis of coronary artery disease and consequent percutaneous coronary intervention in 1 patient. Elevated NT-proBNP levels are present in 23% of patients 50 years and older undergoing bariatric surgery. In 37% of them, there was echocardiographic evidence for structural and/or functional remodeling. Further studies are needed to assess if these preliminary results warrant routine application of NT-proBNP to identify patients at risk for CV complications after bariatric surgery. • This study assessed NT-proBNP as a cardiac screening tool in bariatric patients. • Elevated NT-proBNP levels were present in 23% of patients ≥50 years. • In 37% of them (n=25), echocardiography showed LV dysfunction or heart failure. • NT-proBNP is a non-invasive tool that can detect new CV diseases in bariatric patients [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
15. PO-05-202 FIRST DRAFT OF A NOVEL PLN P.ARG14DEL HEART FAILURE RISK MODEL TO POTENTIALLY AID PATIENT SELECTION FOR FUTURE GENE THERAPY.
- Author
-
der Heide, Myrthe Y. van, Verstraelen, Tom, van Lint, Freyja, Bosman, Laurens P., Brouwer, Remco de, Proost, Virginnio, Germans, Tjeerd, Dickhoff, Cathelijne, Schoonderwoerd, Bas, Houweling, Arjan, Gimeno-Blanes, Juan, de Boer, Rudolf, Cox, Moniek, Tintelen, Peter van, and Wilde, Arthur A.
- Published
- 2023
- Full Text
- View/download PDF
16. Feasibility Of Artificial Intelligence Automated Detection And Classification Of Heart Failure From Routine Electronic Health Records.
- Author
-
Oo, Mon Myat, Tromp, Jasper, Gao, Chuang, Hummel, Y.M., Guignard-Duff, Magalie, Cole, Christian, Jefferson, Emily, Hare, James, de Boer, Rudolf A, Voors, Adriaan, Lam, Carolyn S P, and Lang, Chim C
- Abstract
The increasing availability of electronic health records (EHRs), including not only medical records but also imaging DICOMs, offers opportunities for enhanced patient care through automated case detection and surveillance. We hypothesized that artificial intelligence (AI) automation could be used to identify cases of heart failure (HF) and classify the type of HF (with preserved or reduced ejection fraction [HFpEF or HFrEF]) from routine EHR surveillance. We performed a population-based cohort study of EHR data covering the population of Tayside and Fife since 1993, covering ∼20% of the Scottish population. Using a patient-specific identifier, linkage to other clinical datasets was possible, including community-dispensed prescriptions, echocardiography DICOM images, hospital admissions (Scottish Morbidity Record), and mortality data (General Registry Office). A combination of keyword search of medical records and AI automated reading of stored echocardiographic DICOM images (Us2.ai) was used to identify patients with HFpEF, HFrEF and controls without HF. Verification of the final diagnosis was performed through manual review of medical records, measurement of natriuretic peptides in stored blood samples of identified patients, and comparison of clinical outcomes among groups. Among 3680 patient records with linkage to echocardiographic DICOMs and blood samples, we identified 236 patients with HFpEF, 156 with HFrEF, and 185 controls (Table). Compared to HFrEF, patients with HFpEF were older, more often women and had less coronary artery disease. Compared to controls, patients with HFpEF and HFrEF had greater LV mass, higher mitral E/e' ratio, higher pulmonary artery systolic pressure, more impaired LV strain and RV dysfunction. While majority of patients with HFrEF were on guideline-directed medical therapy, a gap in treatment was identified for mineralocorticoid receptor antagonists. NT-proBNP was higher in HFpEF, and even higher in HFrEF, compared to controls. During a median follow up time of 1089 days, 39% of HFpEF and 63% of HFrEF experienced hospitalization or death, compared to only 5% of controls. We demonstrate the feasibility of AI-automated detection and classification of HF from routine surveillance of electronic health data, yielding cohorts with clinical and echocardiographic characteristics similar to epidemiologic studies, with raised natriuretic peptides and poor outcomes expected in these patient populations. Such AI-assisted electronic surveillance may have application in automated monitoring of clinical records for early disease detection, treatment quality improvement initiatives, and case finding for clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. HE4 Serum Levels Are Associated with Heart Failure Severity in Patients With Chronic Heart Failure.
- Author
-
Piek, Arnold, Meijers, Wouter C., Schroten, Nicolas F., Gansevoort, Ron T., de Boer, Rudolf A., and Silljé, Herman H.W.
- Abstract
Background: The novel biomarker human epididymis protein 4 (HE4) shows prognostic value in acute heart failure (HF) patients. We measured HE4 levels in patients with chronic heart failure (CHF) and correlated them to HF severity, kidney function, and HF biomarkers, and determined its predictive value.Methods: Serum HE4 levels in patients (n = 101) with stable CHF with reduced left ventricular ejection fraction (LVEF <45%) from the Vitamin D CHF (VitD-CHF) study (NCT01092130) were compared with those in age- and sex-matched healthy control subjects (n = 58) from the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study.Results: HE4 levels were higher in CHF compared with control subjects (69.2 pmol/L [interquartile range 55.6-93.8] vs 56.1 pmol/L [46.6-69.0]; P < .001) and were higher with increasing New York Heart Association functional class. Levels were associated with HF risk factors, including age, gender, diabetes, smoking and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP). HE4 demonstrated strong associations with kidney function and HF fibrosis biomarkers. In a multivariable model, we identified creatinine, NT-proBNP, galectin-3, high-sensitive troponin T, and smoking as factors associated with HE4. Independently from these factors, HE4 levels predicted death and HF rehospitalization (5-year follow-up, hazard ratio 3.8; confidence interval 1.31-11.1; P = .014).Conclusions: HE4 levels are increased in CHF, correlate with HF severity and kidney function, and predict HF outcome. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
18. Urinary potassium excretion and risk of cardiovascular events.
- Author
-
Kieneker, Lyanne M., Gansevoort, Ron T., de Boer, Rudolf A., Brouwers, Frank P., Feskens, Edith J. M., Geleijnse, Johanna M., Navis, Gerjan, Bakker, Stephan J. L., and Joosten, Michel M.
- Subjects
CARDIOVASCULAR disease diagnosis ,CARDIOVASCULAR diseases ,PATIENTS ,CARDIOVASCULAR disease treatment ,ALCOHOL drinking & health ,HEALTH ,SMOKING ,ALBUMINURIA ,EDUCATIONAL attainment ,ANTHROPOMETRY ,BLOOD pressure ,CONFIDENCE intervals ,CORONARY disease ,STATISTICAL correlation ,ALCOHOL drinking ,HEART failure ,LONGITUDINAL method ,MAGNESIUM ,SCIENTIFIC observation ,POTASSIUM ,PROBABILITY theory ,RESEARCH funding ,SODIUM ,STATISTICAL hypothesis testing ,STROKE ,BODY mass index ,PROPORTIONAL hazards models ,DATA analysis software ,DESCRIPTIVE statistics ,ODDS ratio ,DIAGNOSIS - Abstract
Background: Observational studies on dietary potassium and risk of cardiovascular disease (CVD) have reported weak-to-modest inverse associations. Long-term prospective studies with multiple 24-h urinary samples for accurate estimation of habitual potassium intake, however, are scarce. Objective: We examined the association between urinary potassium excretion and risk of blood pressure–related cardiovascular outcomes. Design: We studied 7795 subjects free of cardiovascular events at baseline in the Prevention of Renal and Vascular End-stage Disease study, a prospective, observational cohort with oversampling of subjects with albuminuria at baseline. Main cardiovascular outcomes were CVD [including ischemic heart disease (IHD), stroke, and vascular interventions], IHD, stroke, and new-onset heart failure (HF). Potassium excretion was measured in two 24-h urine specimens at the start of the study (1997–1998) and midway through follow-up (2001–2003). Results: Baseline median urinary potassium excretion was 70 mmol/24 h (IQR: 56–84 mmol/24 h). During a median follow-up of 10.5 y (IQR: 9.9–10.8 y), a total of 641 CVD, 465 IHD, 172 stroke, and 265 HF events occurred. After adjustment for age and sex, inverse associations were observed between potassium excretion and risk [HR per each 26- mmol/24-h (1-g/d) increase; 95% CI] of CVD (0.87; 0.78, 0.97) and IHD (0.86; 0.75, 0.97), as well as nonsignificant inverse associations for risk of stroke (0.85; 0.68, 1.06) and HF (0.94; 0.80, 1.10). After further adjustment for body mass index, smoking, alcohol consumption, education, and urinary sodium and magnesium excretion, urinary potassium excretion was not statistically significantly associated with risk (multivariable- adjusted HR per 1-g/d increment; 95% CI) of CVD (0.96; 0.85, 1.09), IHD (0.90; 0.81, 1.04), stroke (1.09; 0.86, 1.39), or HF (0.99; 0.83, 1.18). No associations were observed between the sodium-to-potassium excretion ratio and risk of CVD, IHD, stroke, or HF. Conclusion: In this cohort with oversampling of subjects with albuminuria at baseline, urinary potassium excretion was not independently associated with a lower risk of cardiovascular events. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
19. Left-dominant arrhythmogenic cardiomyopathy in a large family: Associated desmosomal or nondesmosomal genotype?
- Author
-
Groeneweg, Judith A., van der Zwaag, Paul A., Jongbloed, Jan D.H., Cox, Moniek G.P.J., Vreeker, Arnold, de Boer, Rudolf A., van der Heijden, Jeroen F., van Veen, Toon A.B., McKenna, William J., van Tintelen, J. Peter, Dooijes, Dennis, and Hauer, Richard N.W.
- Abstract
Background: Arrhythmogenic cardiomyopathy (AC) is considered a predominantly right ventricular (RV) desmosomal disease. However, left-dominant forms due to desmosomal gene mutations, including PKP2 variant c.419C>T, have been described. Recently, a nondesmosomal phospholamban (PLN) mutation (c.40_42delAGA) has been identified, causing dilated cardiomyopathy and arrhythmias. Objective: To gain more insight into pathogenicity of the PKP2 variant c.419C>T by cosegregation analysis of the PKP2 variant c.419C>T vs the PLN mutation c.40_42delAGA. Methods: A Dutch family (13 family members, median age 49 years, range 34–71 years) with ventricular tachycardia underwent (1) meticulous phenotypic characterization and (2) screening of 5 desmosomal genes (PKP2, DSC2, DSG2, DSP, JUP) and PLN. Results: Six family members fulfilled 2010 AC Task Force Criteria. Seven had signs of left ventricular (LV) involvement (inverted T waves in leads V
4 –V6 , LV wall motion abnormalities and late enhancement, and reduced LV ejection fraction), including 6 family members with proven AC. The PKP2 variant c.419C>T was found as a single variant in 3 family members, combined with the PLN mutation c.40_42delAGA in 3 others. PLN mutation was found in 9 family members, including the 6 with AC and all 7 with LV involvement. The PLN mutation c.40_42delAGA was found as a single mutation in 6, combined with the PKP2 variant c.419C>T in 3 others. A low-voltage electrocardiogram was seen in 4 of 9 PLN mutation-positive subjects. None of the family members with the single PKP2 variant showed any sign of RV or LV involvement. Conclusions: The PLN mutation c.40_42delAGA cosegregates with AC and with electrocardiographic and structural LV abnormalities. In this family, there was no evidence of disease-causing contribution of the PKP2 variant c.419C>T. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
20. Prognostic value of renin and prorenin in heart failure patients with decreased kidney function.
- Author
-
Szymanski, Mariusz K., Damman, Kevin, van Veldhuisen, Dirk J., van Gilst, Wiek H., Hillege, Hans L., and de Boer, Rudolf A.
- Abstract
Background: The renin-angiotensin-aldosterone system (RAAS) plays a key role in the progression of heart failure (HF) and concomitant kidney dysfunction. Despite the use of RAAS blockade, sustained activation of RAAS has been suggested to link with adverse outcome. We aimed to investigate the prognostic value of active plasma renin concentration (APRC) and prorenin in patients with HF treated with RAAS-blocking agents and its relationship with kidney function parameters. Methods: One hundred clinically stable patients with HF, treated with RAAS-blocking agents, were studied. Renal function parameters including effective renal plasma flow and glomerular filtration rate were measured invasively. The combined end point consisted of all-cause mortality, heart transplantation, and admission to hospital for HF. Results: Mean age was 58 ± 12 years, and 76% were men. Mean left ventricular ejection fraction was 28 ± 9, and median APRC levels were 24.3 ng/mL per hour. Active plasma renin concentration was most strongly associated with mean arterial pressure (r = 0.60, P < .001). In multivariate linear regression analysis, age, mean arterial pressure, angiotensin II concentration, and use of aldosterone antagonists were significantly related with APRC (adjusted R
2 = 0.53). Patients in the highest quartile of APRC had a worse prognosis. In multivariate analysis, APRC remained associated with worse prognosis: HR 2.87 (95% CI 1.14-7.20), P = .025. Prorenin did not show prognostic value. The prognostic value of APRC was strongest in patients with decreased kidney function. Conclusions: Our data indicate that APRC is a strong prognostic factor in patients with HF in the presence of RAAS inhibition, especially in patients with kidney dysfunction. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
21. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT).
- Author
-
Brouwers, Frank P., Asselbergs, Folkert W., Hillege, Hans L., de Boer, Rudolf A., Gansevoort, Ron T., van Veldhuisen, Dirk J., and van Gilst, Wiek H.
- Abstract
Background: The PREVEND IT investigated whether treatment targeted at lowering urinary albumin excretion (UAE) would reduce adverse cardiovascular events. We obtained extended follow-up data to approximately 10 years to investigate the long-term effects of fosinopril 20 mg and pravastatin 40 mg on cardiovascular outcomes in subjects with UAE >15 mg per 24 hours. Methods: The original PREVEND IT consisted of 864 participants and 839 survivors after 4 years. For every survivor, the primary end point determined by the combined incidence of cardiovascular mortality and hospitalization for cardiovascular morbidity was registered in several national databases and electronic hospital systems. Results: Mean total follow-up of the extended PREVEND IT was 9.5 years (range 9.4-10.7 years). Four years of treatment with fosinopril was not associated with a reduction in the primary end point compared with placebo (hazard ratio 0.87, 95% CI 0.61-1.24 [P = .42]) during long-term follow-up. After 9.5 years, subjects with a baseline UAE in the upper quintile (>50 mg/24 hours) had a total event rate of 29.5% and were at a higher risk for developing cardiovascular disease compared with less UAE (hazard ratio 2.03, 95% CI 1.38-2.97 [P ≤ .01]). In addition, 4 years of fosinopril treatment resulted in a risk reduction of 45% (95% CI 6%-75% [P = .04]) in this group compared with placebo. Subjects originally assigned to pravastatin had no overall risk reduction in the primary end point (P = .99). Conclusions: Elevated UAE is associated with increased cardiovascular mortality and morbidity after 9.5 years of follow-up, with a doubling of the risk if the UAE is >50 mg per 24 hours. In this group, the benefits of 4-year treatment with fosinopril were sustained during posttrial follow-up for cardiovascular mortality and morbidity. We propose that UAE be used to estimate risk in the general population and that large clinical trials be designed to confirm the hypothesis that angiotensin-converting enzyme–inhibitor treatment may be beneficial in patients with mildly elevated UAE despite the absence of other comorbidities. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
22. Polymorphisms of Adrenoceptors are Not Associated With an Increased Risk of Adverse Event in Heart Failure: A MERIT-HF Substudy.
- Author
-
Savva, Jacqueline, Maqbool, Azhar, White, Hazel L., Galloway, Stacey L., Yuldasheva, Nadira Y., Ball, Stephen G., West, Robert M., De Boer, Rudolf A., Van Veldhuisen, Dirk J., and Balmforth, Anthony J.
- Abstract
Abstract: Background: Enhanced sympathetic activation has a central role in the development of heart failure (HF). We assessed whether the α
2C -adrenoceptor (Del322-325) polymorphism exclusively or in combination with a β1 -adrenoceptor (Arg389) polymorphism, each with known independent effects on sympathetic function, were associated with an increased risk of adverse events in HF. Methods and Results: A total of 526 patients enrolled in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure study were genotyped for both adrenoceptor polymorphisms. The distribution of α2C genotypes was similar between the event and nonevent groups. However, a reduced prevalence of the Del322-325 allele was found in individuals with ischemic congestive HF (P =.022). Patients possessing both the α2C Del322-325 and β1 Arg389 alleles had no increased risk of events. Adjusting for confounding variables and the β1 Arg389Gly polymorphism, the odds ratio of being ins/del + del/del for the α2C Del322-325 and having an event was 0.89 with 95% CI 0.49–1.63, P =.715. Similarly, adjusting for confounding variables and the α2C Del322-325 polymorphism the odds ratio of being Arg/Arg or Arg/Gly for the β1 Arg389Gly polymorphism and having an event was 1.13 with 95% CI 0.52–2.17, P =.864. Conclusions: The α2C Del322-325 polymorphism exclusively or in combination with the β1 Arg389 allele is not associated with an increased risk of adverse events in HF. [Copyright &y& Elsevier]- Published
- 2009
- Full Text
- View/download PDF
23. Both antiplatelet and anticoagulant therapy may favorably affect outcome in patients with advanced heart failure. A retrospective analysis of the PRIME-II trial
- Author
-
de Boer, Rudolf A., Hillege, Hans L., Tjeerdsma, Geert, Verheugt, Freek W.A., and van Veldhuisen, Dirk J.
- Subjects
- *
HEART diseases , *THERAPEUTICS , *CARDIAC arrest , *ATRIAL fibrillation - Abstract
Abstract: Introduction: Current guidelines of chronic heart failure (CHF) do not recommend the use of oral anticoagulants (OAC) or antiplatelet therapy (APT). We performed a post-hoc analysis to evaluate the effect of the use of anti-thrombotic therapy with APT and OAC. Patients and methods: We examined 427 patients with advanced CHF, and assessed the effects of the use of APT or OAC at baseline on mortality. We employed a Cox-proportional hazard model to value the effects of APT or OAC use. Results: After a mean follow-up of 3.4 years (range 2.0–5.4), 214 patients died (51%). Forty-one (41) percent (95%CI: 29–53%) of the patients on APT died, and 52% (47–57%) of the patients not on APT (P=0.07). Forty-eight (48) percent (42–54%) of the patients on OAC died, and 55% (46–63%) of the patients not on OAC (P=0.20). This effect of OAC was seen both in patients in sinus rhythm and in atrial fibrillation. After adjusting for important prognostic variables, such as age, LVEF, renal function, and NYHA class, both the use of APT (hazard ratio (HR) 0.62, 95% confidence interval (CI) 0.40–0.97; P=0.04) and the use of OAC (HR 0.60, 95%–CI 0.43–0.83; P<0.01) were related to an improved prognosis. Conclusion: This post-hoc analysis suggests that in CHF patients the use of APT or OAC is associated with a higher survival. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
24. Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure
- Author
-
Tjeerdsma, Geert, de Boer, Rudolf A., Boomsma, Frans, van den Berg, Maarten P., Pinto, Yigal M., and van Veldhuisen, Dirk J.
- Subjects
- *
HEART failure , *PEPTIDES , *NEUROHORMONES - Abstract
Background: Brain natriuretic peptide (BNP) levels have been used to assess clinical status and predict prognosis of patients with chronic heart failure (CHF). However, BNP levels can only be measured in specialized laboratories which has hampered its use in daily clinical practice. We compared a new, rapid, BNP assay with a conventional BNP measurement and evaluated the applicability to current practice by comparing it with standard clinical parameters. Methods: BNP levels were determined in 78 stable CHF patients and 20 controls. The severity of CHF was assessed by determination of New York Heart Association functional class (NYHA), left ventricular ejection fraction (LVEF) and peak oxygen consumption (peak Vo2), and these parameters were compared to BNP levels. Results: Overall, rapid BNP assessment was highly correlated with the conventional BNP assay (r=0.95, P<0.0001). In the higher ranges (>200 pmol/l), however, correlation was less accurate, and tended to overestimate. BNP levels also strongly correlated with both NYHA class, LVEF and peak Vo2 (all P<0.001). A cut-off value for BNP of 20 pmol/l yielded a sensitivity of 91% and a specificity of 92% to detect the presence of left ventricular systolic dysfunction. Conclusions: Rapid measurement of BNP levels is comparable to conventional BNP measurement and strongly correlated to clinical tests that are currently used to stratify CHF patients. Wider use of this method may yield a reduction of costly and time-consuming clinical tests and may reduce the medical burden of CHF. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
25. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial.
- Author
-
Kondo, Toru, Mogensen, Ulrik M., Talebi, Atefeh, Gasparyan, Samvel B., Campbell, Ross T., Docherty, Kieran F., de Boer, Rudolf A., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Sabatine, Marc S., Bengtsson, Olof, Sjöstrand, Mikaela, Vaduganathan, Muthiah, Solomon, Scott D., Jhund, Pardeep S., and McMurray, John J.V.
- Subjects
- *
DAPAGLIFLOZIN , *VENTRICULAR ejection fraction , *HEART failure patients , *HEART failure ,CARDIOVASCULAR disease related mortality - Abstract
Conventional time-to-first-event analyses cannot incorporate recurrent hospitalizations and patient well-being in a single outcome. To overcome this limitation, we tested an integrated measure that includes days lost from death and hospitalization, and additional days of full health lost through diminished well-being. The effect of dapagliflozin on this integrated measure was assessed in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial, which examined the efficacy of dapagliflozin, compared with placebo, in patients with NYHA functional class II to IV heart failure and a left ventricular ejection fraction ≤40%. Over 360 days, patients in the dapagliflozin group (n = 2,127) lost 10.6 ± 1.0 (2.9%) of potential follow-up days through cardiovascular death and heart failure hospitalization, compared with 14.4 ± 1.0 days (4.0%) in the placebo group (n = 2,108), and this component of all measures of days lost accounted for the greatest between-treatment difference (−3.8 days [95% CI: −6.6 to −1.0 days]). Patients receiving dapagliflozin also had fewer days lost to death and hospitalization from all causes vs placebo (15.5 ± 1.1 days [4.3%] vs 20.3 ± 1.1 days [5.6%]). When additional days of full health lost (ie, adjusted for Kansas City Cardiomyopathy Questionnaire–overall summary score) were added, total days lost were 110.6 ± 1.6 days (30.7%) with dapagliflozin vs 116.9 ± 1.6 days (32.5%) with placebo. The difference in all measures between the 2 groups increased over time (ie, days lost by death and hospitalization −0.9 days [−0.7%] at 120 days, −2.3 days [−1.0%] at 240 days, and −4.8 days [−1.3%] at 360 days). Dapagliflozin reduced the total days of potential full health lost due to death, hospitalizations, and impaired well-being, and this benefit increased over time during the first year. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure; NCT03036124) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Activation of liver X receptor-α reduces activation of the renal and cardiac renin–angiotensin–aldosterone system.
- Author
-
Kuipers, Irma, van der Harst, Pim, Kuipers, Folkert, van Genne, Linda, Goris, Maaike, Lehtonen, Jukka Y., van Veldhuisen, Dirk J., van Gilst, Wiek H., and de Boer, Rudolf A.
- Published
- 2010
- Full Text
- View/download PDF
27. Specific MAP-Kinase Blockade Protects against Renal Damage in Homozygous TGR(mRen2)27 Rats.
- Author
-
de Borst, Martin H., Navis, Gerjan, de Boer, Rudolf A., Huitema, Sippie, Vis, Lotte M., van Gilst, Wiek H., and van Goor, Harry
- Published
- 2003
- Full Text
- View/download PDF
28. Aortic regurgitation, a forgotten valve disease in hypertrophic cardiomyopathy?
- Author
-
Westenbrink, B. Daan, de Boer, Rudolf A., and Vliegenthart, Rozemarijn
- Subjects
- *
AORTIC valve insufficiency , *HYPERTROPHIC cardiomyopathy , *VENTRICULAR outflow obstruction , *HEART valve diseases , *ECHOCARDIOGRAPHY , *CARDIAC hypertrophy , *MAGNETIC resonance imaging , *NUCLEAR magnetic resonance spectroscopy - Published
- 2020
- Full Text
- View/download PDF
29. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.
- Author
-
Chatur, Safia, Vaduganathan, Muthiah, Claggett, Brian L., Mc Causland, Finnian R., Desai, Akshay S., Jhund, Pardeep S., de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe A., Shah, Sanjiv J., Sabatine, Marc S., Kober, Lars, Ponikowski, Piotr, Merkely, Bela, Petersson, Magnus, Langkilde, Anna Maria, and McMurray, John J.V.
- Subjects
- *
HEART failure patients , *DAPAGLIFLOZIN , *KIDNEY physiology , *PROPORTIONAL hazards models , *KIDNEY failure - Abstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are guideline recommended in the management of heart failure (HF). Although these therapies can be initiated even in patients with comorbid chronic kidney disease, some patients may face deterioration of kidney function over time. In this study, the authors sought to examine the safety and efficacy of continuing SGLT2 inhibitors in HF when the estimated glomerular filtration rate (eGFR) falls below thresholds for initiation. Associations between a deterioration of eGFR to <25 mL/min/1.73 m2, efficacy, and safety outcomes and treatment with dapagliflozin were evaluated in time-updated Cox proportional hazard models in a participant-level pooled analysis of the DAPA-HF (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trials. Among 11,007 patients, 347 (3.2%) experienced a deterioration of eGFR to <25 mL/min/1.73 m2 at least once in follow-up. These patients had a higher risk of the primary composite outcome (HR: 1.87; 95% CI: 1.48-2.35; P < 0.001). The risk of the primary outcome was lower with dapagliflozin compared with placebo among patients who did (HR: 0.53; 95% CI: 0.33-0.83) as well as did not (HR: 0.78; 95% CI: 0.72-0.86) experience deterioration of eGFR to <25 mL/min/1.73 m2 (P interaction = 0.17). The risk of safety outcomes, including drug discontinuation, was higher among patients with deterioration of eGFR to <25 mL/min/1.73 m2; however, rates remained similar between treatment groups including among those who remained on study drug. Patients with deterioration of eGFR to <25 mL/min/1.73 m2 had elevated risks of cardiovascular outcomes yet appeared to benefit from continuation of dapagliflozin with no excess in safety outcomes between treatment groups. The benefit-to-risk ratio may favor continuation of dapagliflozin treatment in patients with HF experiencing deterioration of kidney function. Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124 ; and Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.
- Author
-
Kondo, Toru, Wang, Xiaowen, Yang, Mingming, Jhund, Pardeep S., Claggett, Brian L., Vaduganathan, Muthiah, Hernandez, Adrian F., Lam, Carolyn S.P., Inzucchi, Silvio E., Martinez, Felipe A., de Boer, Rudolf A., Kosiborod, Mikhail N., Desai, Akshay S., Køber, Lars, Ponikowski, Piotr, Sabatine, Marc S., Langkilde, Anna Maria, Petersson, Magnus, Zaozerska, Natalia, and Bachus, Erasmus
- Subjects
- *
HEART failure , *HEART failure patients , *DAPAGLIFLOZIN , *VENTRICULAR ejection fraction ,CARDIOVASCULAR disease related mortality - Abstract
Because clinical characteristics and prognosis vary by geographic region in patients with heart failure (HF), the response to treatment may also vary. A previous report suggested that the efficacy of sodium-glucose cotransporter-2 inhibitor efficacy in heart failure with reduced ejection fraction (HFrEF) may be modified by region. The goal of this study was to examine the efficacy and safety of dapagliflozin in patients with HF according to geographic region. We conducted a patient-level pooled analysis of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trials, which evaluated the effects of dapagliflozin in HFrEF and heart failure with mildly reduced ejection fraction (HFmrEF)/heart failure with preserved ejection fraction (HFpEF), respectively. The primary outcome was the composite of worsening HF or cardiovascular death. Among 11,007 patients, 5,159 (46.9%) were enrolled in Europe, 1,528 (13.9%) in North America, 1,998 (18.2%) in South America, and 2,322 (21.1%) in Asia. The rate of the primary outcome (per 100 person-years) was higher in North America (13.9 [95% CI: 12.5-15.4]) than in other regions: Europe 10.8 (95% CI: 10.1-11.5), South America 10.0 (95% CI: 9.0-11.1), and Asia 10.5 (95% CI: 9.5-11.5). The benefit of dapagliflozin on the primary outcome was not modified by region: dapagliflozin vs placebo HR: Europe, 0.85 (95% CI: 0.75-0.96); North America, 0.75 (95% CI: 0.61-0.93); South America, 0.72 (95% CI: 0.58-0.89); and Asia, 0.74 (95% CI: 0.61-0.91) (P interaction = 0.40). This was the same when evaluated separately for HFrEF (P interaction = 0.39) and HFmrEF/HFpEF (P interaction = 0.84). Patients in North America discontinued randomized treatment more frequently than did those elsewhere (placebo discontinuation: 21.8% in North America vs 6.4% in South America), but discontinuation rates did not differ between placebo and dapagliflozin by region. The efficacy and safety of dapagliflozin were consistent across global regions despite geographic differences in patient characteristics, background treatment, and event rates. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. PHARMACOKINETIC AND PHARMACODYNAMIC RESPONSE TO ORAL AND SUBCUTANEOUS FUROSEMIDE ADMINISTRATION: FIRST EXPERIENCES WITH A NOVEL BUFFERED FUROSEMIDE FORMULATION IN PATIENTS WITH CHRONIC HEART FAILURE.
- Author
-
De Boer, Rudolf A., ter Maaten, Jozine, Damman, Kevin, Muntendam, Pieter, Sica, Domenic A., van Veldhuisen, Dirk, and Pitt, Bertram
- Subjects
- *
PHARMACOKINETICS , *HEART failure patients , *HEART failure treatment , *PHARMACODYNAMICS , *ORAL medication , *FUROSEMIDE , *THERAPEUTICS - Published
- 2016
- Full Text
- View/download PDF
32. Low-dose digoxin in heart failure
- Author
-
van Veldhuisen, Dirk J. and de Boer, Rudolf A.
- Published
- 2009
- Full Text
- View/download PDF
33. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure.
- Author
-
Docherty, Kieran F., McDowell, Kirsty, Welsh, Paul, Osmanska, Joanna, Anand, Inder, de Boer, Rudolf A., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., O'Meara, Eileen, Ponikowski, Piotr, Schou, Morten, Berg, David D., Sabatine, Marc S., Morrow, David A., Jarolim, Petr, Hammarstedt, Ann, Sjöstrand, Mikaela, Langkilde, Anna Maria, and Solomon, Scott D.
- Subjects
- *
HEART failure patients , *DAPAGLIFLOZIN , *CARBOHYDRATES , *ANTIGENS ,CARDIOVASCULAR disease related mortality - Abstract
Elevated circulating carbohydrate antigen 125 (CA125) is a marker of congestion and a predictor of outcomes in acute heart failure (HF). Less is known about CA125 in chronic ambulatory HF with reduced ejection fraction. This study examined the association between baseline CA125 (and changes in CA125) and outcomes in patients with HF with reduced ejection fraction in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; NCT03036124) trial and its relationship with the effect of dapagliflozin. The primary outcome was a composite of a first episode of worsening HF or cardiovascular death. CA125 was measured at baseline and 12 months following randomization. Median baseline CA125 was 13.04 U/mL (IQR: 8.78-21.13 U/mL) in 3,123 of 4,774 patients with available data. Compared with CA125 ≤35 U/mL (upper limit of normal), patients with CA125 >35 U/mL were at a higher risk of the primary outcome (adjusted HR: 1.59; 95% CI: 1.29-1.96). The adjusted risks of the primary outcome relative to quartile 1 (Q1) (≤8.78 U/mL) were as follow: Q2, 8.79-13.04 U/mL (HR: 0.94; 95% CI: 0.71-1.24); Q3, 13.05-21.13 U/mL (HR: 1.22; 95% CI: 0.94-1.59); Q4, ≥21.14 U/mL (HR: 1.63; 95% CI: 1.28-2.09). The beneficial effect of dapagliflozin compared with placebo on the primary outcome was consistent whether CA125 was analyzed in quartiles (interaction P = 0.13) or as a continuous variable (interaction P = 0.75). The placebo-corrected relative change in CA125 at 12 months was −5.2% (95% CI: −10.6% to 0.5%; P = 0.07). In DAPA-HF, elevated CA125 levels were an independent predictor of the risk of worsening HF or cardiovascular death. Dapagliflozin reduced the risk of worsening HF or cardiovascular death regardless of baseline CA125. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Hemoglobin levels and new-onset heart failure in the community.
- Author
-
Klip, IJsbrand T., Postmus, Douwe, Voors, Adriaan A., Brouwers, Frank P.J., Gansevoort, Ron T., Bakker, Stephan J.L., Hillege, Hans L., de Boer, Rudolf A., van der Harst, Pim, van Gilst, Wiek H., van Veldhuisen, Dirk J., and van der Meer, Peter
- Abstract
Background In established cardiovascular disease and heart failure (HF), low hemoglobin levels are associated with unfavorable outcome. Whether hemoglobin levels are associated with the development of new-onset HF in the population is unclear. This study sought to investigate the relationship between hemoglobin levels and development of new-onset HF in the community. Methods In 6,744 patients from PREVEND, a prospective, community-based, cohort study, we analyzed the relationship between hemoglobin levels and the risk of new-onset HF. Results Mean age (±SD) was 53 ± 12 years, 49.8% was male, and mean hemoglobin level was 13.7 ± 1.2 g/dL. During a median follow-up of 8.3 years (interquartile range 7.8-8.9), 217 subjects (3.2%) were newly diagnosed with HF. The association between hemoglobin levels and the risk for new-onset HF was U shaped ( P < .001), remaining significant after full adjustment in a multivariable model with established cardiovascular risk factors ( P = .015). Furthermore, a increased annual HF incidence was already observed in subjects with high-normal hemoglobin levels (men >16 g/dL or women >15 g/dL; P = .041), whereas on the other side of the distribution, only severe anemia (men <11 g/dL or women <10 g/dL; P = .018) was associated with a higher annual incidence. Conclusions The impact of hemoglobin level on the risk of new-onset HF in the community is best described as U shaped. Interestingly, higher hemoglobin levels, already within the high-reference range, are associated with an increased incidence. This in contrast to anemia, where a higher annual HF incidence was only observed for severe anemia. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
35. Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.
- Author
-
Corro Ramos, Isaac, Versteegh, Matthijs M., de Boer, Rudolf A., Koenders, Jolanda M. A., Linssen, Gerard C. M., Meeder, Joan G., Rutten-van Mölken, Maureen P. M. H., and Ramos, Isaac Corro
- Abstract
Objectives: To describe the adaptation of a global health economic model to determine whether treatment with the angiotensin receptor neprilysin inhibitor LCZ696 is cost effective compared with the angiotensin-converting enzyme inhibitor enalapril in adult patients with chronic heart failure with reduced left ventricular ejection fraction in the Netherlands; and to explore the effect of performing the cost-effectiveness analyses according to the new pharmacoeconomic Dutch guidelines (updated during the submission process of LCZ696), which require a value-of-information analysis and the inclusion of indirect medical costs of life-years gained.Methods: We adapted a UK model to reflect the societal perspective in the Netherlands by including travel expenses, productivity loss, informal care costs, and indirect medical costs during the life-years gained and performed a preliminary value-of-information analysis.Results: The incremental cost-effectiveness ratio obtained was €17,600 per quality-adjusted life-year (QALY) gained. This was robust to changes in most structural assumptions and across different subgroups of patients. Probability sensitivity analysis results showed that the probability that LCZ696 is cost-effective at a €50,000 per QALY threshold is 99.8%, with a population expected value of perfect information of €297,128. On including indirect medical costs of life-years gained, the incremental cost-effectiveness ratio was €26,491 per QALY gained, and LCZ696 was 99.46% cost effective at €50,000 per QALY, with a population expected value of perfect information of €2,849,647.Conclusions: LCZ696 is cost effective compared with enalapril under the former and current Dutch guidelines. However, the (monetary) consequences of making a wrong decision were considerably different in both scenarios. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
36. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials.
- Author
-
Meijers, Wouter C., Januzzi, James L., deFilippi, Christopher, Adourian, Aram S., Shah, Sanjiv J., van Veldhuisen, Dirk J., and de Boer, Rudolf A.
- Abstract
Background: Rehospitalization is a major cause for heart failure (HF)–related morbidity and is associated with considerable loss of quality of life and costs. The rate of unplanned rehospitalization in patients with HF is unacceptably high; current risk stratification to identify patients at risk for rehospitalization is inadequate. We evaluated whether measurement of galectin-3 would be helpful in identifying patients at such risk. Methods: We analyzed pooled data from patients (n = 902) enrolled in 3 cohorts (COACH, n = 592; PRIDE, n = 181; and UMD H-23258, n = 129) originally admitted because of HF. Mean patient age was between 61.6 and 72.9 years across the cohorts, with a wide range of left ventricular ejection fraction. Galectin-3 levels were measured during index admission. We used fixed and random-effects models, as well as continuous and categorical reclassification statistics to assess the association of baseline galectin-3 levels with risk of postdischarge rehospitalization at different time points and the composite end point all-cause mortality and rehospitalization. Results: Compared with patients with galectin-3 concentrations less than 17.8 ng/mL, those with results exceeding this value were significantly more likely to be rehospitalized for HF at 30, 60, 90, and 120 days after discharge, with odds ratios (ORs) of 2.80 (95% CI 1.41-5.57), 2.61 (95% CI 1.46-4.65), 3.01 (95% CI 1.79-5.05), and 2.79 (95% CI 1.75-4.45), respectively. After adjustment for age, gender, New York Heart Association class, renal function (estimated glomerular filtration rate), left ventricular ejection fraction, and B-type natriuretic peptide, galectin-3 remained an independent predictor of HF rehospitalization. The addition of galectin-3 to risk models significantly reclassified patient risk of postdischarge rehospitalization and fatal event at each time point (continuous net reclassification improvement at 30 days of +42.6% [95% CI +19.9%-65.4%], P < .001). Conclusions: Among patients hospitalized for HF, plasma galectin-3 concentration is useful for the prediction of near-term rehospitalization. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
37. Galectin-3 in a Sample of Hospitalized Class IV NYHA Heart Failure Patients.
- Author
-
De Menezes Falcão, Luiz Filipe and De Boer, Rudolf A.
- Published
- 2013
- Full Text
- View/download PDF
38. Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: An open-label, blinded end point, randomized prospective trial (VitD-CHF trial)
- Author
-
Schroten, Nicolas F, Ruifrok, Willem P T, Kleijn, Lennaert, Dokter, Martin M, Silljé, Herman H, Lambers Heerspink, Hiddo J, Bakker, Stephan J L, Kema, Ido P, van Gilst, Wiek H, van Veldhuisen, Dirk J, Hillege, Hans L, and de Boer, Rudolf A
- Published
- 2013
- Full Text
- View/download PDF
39. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
- Author
-
Kosiborod, Mikhail N., Bhatt, Ankeet S., Claggett, Brian L., Vaduganathan, Muthiah, Kulac, Ian J., Lam, Carolyn S.P., Hernandez, Adrian F., Martinez, Felipe A., Inzucchi, Silvio E., Shah, Sanjiv J., de Boer, Rudolf A., Jhund, Pardeep S., Desai, Akshay S., Fang, James C., Han, Yaling, Comin-Colet, Josep, Vardeny, Orly, Lindholm, Daniel, Wilderäng, Ulrica, and Bengtsson, Olof
- Subjects
- *
HEART failure , *VENTRICULAR ejection fraction , *DAPAGLIFLOZIN , *HEART failure patients , *PATIENTS' attitudes , *CLINICAL deterioration - Abstract
Patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) experience a high burden of symptoms, physical limitations, and poor quality of life; improving health status is a key goal of management. In a prespecified analysis of the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trial, we examine effects of dapagliflozin on health status using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The DELIVER trial randomized patients with symptomatic HFmrEF/HFpEF to dapagliflozin 10 mg or placebo. KCCQ was evaluated at randomization, 1, 4, and 8 months; KCCQ Total Symptom Score (TSS) was a key secondary endpoint. Patients were stratified by KCCQ-TSS tertiles; Cox models examined effects of dapagliflozin on clinical outcomes. We evaluated the effects of dapagliflozin on KCCQ-TSS, Physical Limitations (PLS), Clinical Summary (CSS), and Overall Summary (OSS) domains. Responder analyses compared proportions of dapagliflozin vs placebo-treated patients with clinically meaningful changes in KCCQ. A total of 5,795 patients had baseline KCCQ (median KCCQ-TSS 72.9). The effects of dapagliflozin on reducing cardiovascular death/worsening HF appeared more pronounced in patients with greater baseline symptom burden (lowest-to-highest KCCQ-TSS tertile: HR: 0.70 [95% CI: 0.58-0.84]; 0.81 [95% CI: 0.65-1.01]; 1.07 [95% CI: 0.83-1.37]; P interaction = 0.026). Dapagliflozin improved KCCQ-TSS, -PLS, -CSS, and -OSS at 8 months (2.4, 1.9, 2.3, and 2.1 points higher vs placebo; P < 0.001 for all). Dapagliflozin-treated patients experienced improvements in KCCQ-TSS regardless of EF (P interaction = 0.85). Fewer dapagliflozin-treated patients had deterioration, and more had improvements in all KCCQ domains at 8 months. The clinical benefits of dapagliflozin in HFmrEF/HFpEF appear especially pronounced in those with greater baseline symptom impairment. Dapagliflozin improved all KCCQ domains and the proportion of patients experiencing clinically meaningful changes in health status. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure.
- Author
-
Vaduganathan, Muthiah, Claggett, Brian L., Jhund, Pardeep, de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., Desai, Akshay S., Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.
- Subjects
- *
VENTRICULAR ejection fraction , *DAPAGLIFLOZIN , *MIDDLE age , *OLDER people , *HEART failure , *LEFT heart ventricle , *SODIUM , *TYPE 2 diabetes , *RESEARCH funding , *STROKE volume (Cardiac output) , *GLUCOSE , *HEART physiology - Abstract
Background: Recent guidelines support consideration of sodium-glucose cotransporter-2 inhibitors in the long-term management of heart failure (HF) with mildly reduced or preserved ejection fraction. Patients and clinicians may be interested in the expected lifetime benefits of sodium-glucose cotransporter-2 inhibitors in this population.Objectives: This study aimed to estimate event-free survival gains from long-term use of dapagliflozin in patients with HF with mildly reduced or preserved ejection fraction overall and in clinically relevant subgroups.Methods: In this prespecified analysis of DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure), we applied validated nonparametric age-based methods to extrapolate potential gains in survival free from the primary endpoint (cardiovascular death or worsening HF event) from long-term use of dapagliflozin. Eligible participants had symptomatic HF, left ventricular ejection fraction >40%, elevated natriuretic peptide levels, and structural heart disease. For every year between the ages of 55 and 85 years, we estimated event-free survival using age at randomization rather than time from randomization as the time horizon. Residual lifespan free from a primary endpoint was estimated based on area under the survival curve in each arm.Results: Among 6,263 participants, mean survival free from the primary endpoint for a 65-year-old participant was 12.1 years (95% CI: 11.0-13.2 years) with dapagliflozin and 9.7 years (95% CI: 8.8-10.7 years) with placebo, representing a 2.3-year (95% CI: 0.9-3.8 years) event-free survival gain (P = 0.002). Treatment gains in survival free from the primary endpoint ranged from 2.0 years (95% CI: -0.6 to 4.6 years) in a 55-year-old to 1.2 years (95% CI: -0.1 to 2.4 years) in a 75-year-old patient. Mean event-free survival was greater with dapagliflozin than with placebo across all 14 subgroups.Conclusions: Treatment with dapagliflozin is projected to extend event-free survival by up to 2.0 to 2.5 years among middle-aged and older individuals with HF with mildly reduced or preserved ejection fraction. (DELIVER [Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure]; NCT03619213). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
41. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.
- Author
-
Butt, Jawad H., Kondo, Toru, Jhund, Pardeep S., Comin-Colet, Josep, de Boer, Rudolf A., Desai, Akshai S., Hernandez, Adrian F., Inzucchi, Silvio E., Janssens, Stefan P., Kosiborod, Mikhail N., Lam, Carolyn S.P., Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe, Petersson, Magnus, Shah, Sanjiv J., Thierer, Jorge, Vaduganathan, Muthiah, Verma, Subodh, and Wilderäng, Ulrica
- Subjects
- *
ATRIAL fibrillation , *VENTRICULAR ejection fraction , *DAPAGLIFLOZIN , *LEFT heart ventricle , *EVALUATION research , *RESEARCH funding , *HEART failure , *HEART physiology , *RANDOMIZED controlled trials , *RESEARCH , *STROKE volume (Cardiac output) , *COMPARATIVE studies , *LEFT ventricular dysfunction , *DISEASE complications - Abstract
Background: Atrial fibrillation (AF) is common in heart failure (HF), is associated with worse outcomes compared with sinus rhythm, and may modify the effects of therapy.Objectives: This study examined the effects of dapagliflozin according to the presence or not of AF in the DELIVER (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure) trial.Methods: A total of 6,263 patients with HF with New York Heart Association functional class II-IV, left ventricular ejection fraction >40%, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomized to dapagliflozin or placebo. Clinical outcomes and the effect of dapagliflozin, according to AF status, were examined. The primary outcome was a composite of cardiovascular death or worsening HF.Results: Of the 6,261 patients with data on baseline AF, 43.3% had no AF, 18.0% had paroxysmal AF, and 38.7% had persistent/permanent AF. The risk of the primary endpoint was higher in patients with AF, especially paroxysmal AF, driven by a higher rate of HF hospitalization: no AF, HF hospitalization rate per 100 person-years (4.5 [95% CI: 4.0-5.1]), paroxysmal AF (7.5 [95% CI: 6.4-8.7]), and persistent/permanent AF (6.4 [95% CI: 5.7-7.1]) (P < 0.001). The benefit of dapagliflozin on the primary outcome was consistent across AF types: no AF, HR: 0.89 (95% CI: 0.74-1.08); paroxysmal AF, HR: 0.75 (95% CI: 0.58-0.97); persistent/permanent AF, HR: 0.79 (95% CI: 0.66-0.95) (Pinteraction = 0.49). Consistent effects were observed for HF hospitalization, cardiovascular death, all-cause mortality, and improvement in the KCCQ-TSS.Conclusions: In DELIVER, the beneficial effects of dapagliflozin compared with placebo on clinical events and symptoms were consistent, irrespective of type of AF at baseline. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. [DELIVER]; NCT03619213). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
42. Changes in Galectin-3 Levels over Time Predict Mortality and Morbidity in Chronic HF.
- Author
-
de Boer, Rudolf A., van Veldhuisen, Dirk J., Gullestad, Lars, Ueland, Thor, Aukrust, Pal, Guo, Yu, Adourian, Aram S., and Muntendam, Pieter
- Published
- 2011
- Full Text
- View/download PDF
43. Plasma Galectin-3 Is Associated with Near-Term Rehospitalization in Heart Failure: A Meta-Analysis.
- Author
-
de Boer, Rudolf A., van Veldhuisen, Dirk J., deFilippi, Christopher, Muntendam, Pieter, Adourian, Aram S., Guo, Yu, and Januzzi, James L.
- Published
- 2011
- Full Text
- View/download PDF
44. Influence of Diabetes Mellitus and Hyperglycemia on Prognosis in Patients ≥70 Years Old With Heart Failure and Effects of Nebivolol (Data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure [SENIORS])
- Author
-
de Boer, Rudolf A., Doehner, Wolfram, van der Horst, Iwan C.C., Anker, Stefan D., Babalis, Daphne, Roughton, Michael, Coats, Andrew J., Flather, Marcus D., and van Veldhuisen, Dirk J.
- Subjects
- *
DIABETES in old age , *HYPERGLYCEMIA , *CARDIOVASCULAR diseases in old age , *HEART failure , *VASODILATORS , *HEALTH outcome assessment , *PROGNOSIS ,CARDIOVASCULAR disease related mortality - Abstract
The beneficial effects of β blockers in younger patients with heart failure (HF) due to systolic dysfunction are well established. However, data from patients ≥70 years old with diabetes mellitus and HF are lacking. The Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS] tested the efficacy of the vasodilator β blocker nebivolol in patients ≥70 years old with HF and impaired or preserved left ventricular ejection fraction. In the present analysis, we evaluated the association between diabetes mellitus and baseline glucose levels on the primary outcome (all-cause mortality and cardiovascular hospitalization) and secondary end points, including all-cause mortality, cardiovascular hospitalizations, and cardiovascular mortality. Of 2,128 patients, 555 (26.1%) had diabetes mellitus. Of the 555 patients with diabetes mellitus, 223 (40.2%) experienced the primary end point compared to 484 (30.8%) of the 1,573 nondiabetic patients (p <0.001). For the nondiabetic patients, the rate of the primary outcome for placebo compared to nebivolol was 33.7% for the placebo group and 27.8% for the nebivolol group (hazard ratio 0.78, 95% confidence interval 0.65 to 0.93; p = 0.006). In the diabetic subset, the rate was 40.3% for the placebo group and 40.1% for the nebivolol group (hazard ratio 1.04, 95% confidence interval 0.80 to 1.35, p = 0.773). The subgroup interaction p value was 0.073. The baseline glucose levels in the nondiabetic patients did not significantly affect the outcomes. The effect of diabetes mellitus on outcome was independent of the left ventricular ejection fraction and was most pronounced in those with HF due to a nonischemic etiology. In conclusion, in patients ≥70 years old with HF, diabetes mellitus was associated with a worse prognosis. Nebivolol was less effective in the patients with diabetes and HF than in those with HF but without diabetes who were ≥70 years old. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
45. CLINICAL AND PROGNOSTIC VALUE OF GALECTIN-3, A NOVEL FIBROSIS-ASSOCIATED BIOMARKER. RELATION WITH CLINICAL AND BIOCHEMICAL CORRELATES OF HEART FAILURE.
- Author
-
De Boer, Rudolf A., Lok, Dirk, Hillege, Johannes L., Voors, Adriaan A., van Gilst, Wiek H., Jaarsma, Tiny, and van Veldhuisen, Dirk J.
- Published
- 2010
- Full Text
- View/download PDF
46. Clinical and Prognostic Value of Galectin-3, a Novel Fibrosis-Associated biomarker, in Patients with Chronic Heart Failure.
- Author
-
van Veldhuisen, Dirk J., Lok, Dirk J.A., Damman, Kevin, de Boer, Rudolf A., van der Meer, Peter, Voors, Adriaan A., and Jaarsma, Tiny
- Published
- 2009
- Full Text
- View/download PDF
47. Brugada Syndrome or Brugada Electrocardiogram?
- Author
-
van den Berg, Maarten P., de Boer, Rudolf A., and van Tintelen, J. Peter
- Published
- 2009
- Full Text
- View/download PDF
48. 1031-107 The vascular endothelial growth factor +405 CC promotor polymorphism is associated with an impaired prognosis in patients with chronic heart failure: For the MERIT-HF study group.
- Author
-
Van der Meer, Peter, De Boer, Rudolf A, White, Hazel L, Hall, Alistair S, Hillege, Hans, and Van Veldhuisen, Dirk J
- Subjects
- *
VASCULAR endothelial growth factors , *HEMOGLOBIN polymorphisms , *HEART failure , *HEART transplantation , *DISEASE progression , *PROGNOSIS - Published
- 2004
- Full Text
- View/download PDF
49. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.
- Author
-
Cunningham, Jonathan W., Vaduganathan, Muthiah, Claggett, Brian L., Kulac, Ian J., Desai, Akshay S., Jhund, Pardeep S., de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., McGrath, Martina M., O'Meara, Eileen, Wilderäng, Ulrica, Lindholm, Daniel, Petersson, Magnus, and Langkilde, Anna Maria
- Subjects
- *
VENTRICULAR ejection fraction , *HEART failure , *DAPAGLIFLOZIN , *DIABETIC acidosis , *HOSPITAL patients , *LEFT heart ventricle , *BENZENE , *RESEARCH , *GLYCOSIDES , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *HOSPITAL care , *HEART physiology , *STROKE volume (Cardiac output) ,CARDIOVASCULAR disease related mortality - Abstract
Background: Patients recently hospitalized for heart failure (HF) are at high risk for rehospitalization and death.Objectives: The purpose of this study was to investigate clinical outcomes and response to dapagliflozin in patients with HF with mildly reduced or preserved left ventricular ejection fraction (LVEF) who were enrolled during or following hospitalization.Methods: The DELIVER (Dapagliflozin Evaluation to Improve the LIVES of Patients With PReserved Ejection Fraction Heart Failure) trial randomized patients with HF and LVEF >40% to dapagliflozin or placebo. DELIVER permitted randomization during or shortly after hospitalization for HF in clinically stable patients off intravenous HF therapies. This prespecified analysis investigated whether recent HF hospitalization modified risk of clinical events or response to dapagliflozin. The primary outcome was worsening HF event or cardiovascular death.Results: Of 6,263 patients in DELIVER, 654 (10.4%) were randomized during HF hospitalization or within 30 days of discharge. Recent HF hospitalization was associated with greater risk of the primary outcome after multivariable adjustment (HR: 1.88; 95% CI: 1.60-2.21; P < 0.001). Dapagliflozin reduced the primary outcome by 22% in recently hospitalized patients (HR: 0.78; 95% CI: 0.60-1.03) and 18% in patients without recent hospitalization (HR: 0.82; 95% CI: 0.72-0.94; Pinteraction = 0.71). Rates of adverse events, including volume depletion, diabetic ketoacidosis, or renal events, were similar with dapagliflozin and placebo in recently hospitalized patients.Conclusions: Dapagliflozin safely reduced risk of worsening HF or cardiovascular death similarly in patients with and without history of recent HF hospitalization. Starting dapagliflozin during or shortly after HF hospitalization in patients with mildly reduced or preserved LVEF appears safe and effective. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
50. Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction.
- Author
-
Vaduganathan, Muthiah, Claggett, Brian L., Jhund, Pardeep, Miao, Zi Michael, de Boer, Rudolf A., Lam, Carolyn S.P., Desai, Akshay S., Bengsston, Olof, McMurray, John J.V., and Solomon, Scott D.
- Subjects
- *
HEART failure patients , *VENTRICULAR ejection fraction , *DAPAGLIFLOZIN , *HOSPITAL care - Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.